NCT05974839View on ClinicalTrials.gov

Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)

CompletedOBSERVATIONAL
Enrollment

732

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions
Primary Progressive Multiple Sclerosis
Interventions
OTHER

Ocrelizumab

Non-interventional

Trial Locations (1)

14203

Buffalo Neuroimaging Analysis Center, Buffalo

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

State University of New York at Buffalo

OTHER

NCT05974839 - Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical) | Biotech Hunter | Biotech Hunter